Drug-induced liver injury due to varenicline: a case report
<p>Abstract</p> <p>Background</p> <p>Liver injury due to prescription and nonprescription medications is an expanding public health concern in the United States, with drug-induced liver injury (DILI) being the single most common reason for regulatory actions instituted...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-06-01
|
Series: | BMC Gastroenterology |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1471-230X/12/65 |
id |
doaj-6d20498b08a24300b8ea9ef862b71c4b |
---|---|
record_format |
Article |
spelling |
doaj-6d20498b08a24300b8ea9ef862b71c4b2020-11-25T01:59:20ZengBMCBMC Gastroenterology1471-230X2012-06-011216510.1186/1471-230X-12-65Drug-induced liver injury due to varenicline: a case reportSprague DavidBambha Kiran<p>Abstract</p> <p>Background</p> <p>Liver injury due to prescription and nonprescription medications is an expanding public health concern in the United States, with drug-induced liver injury (DILI) being the single most common reason for regulatory actions instituted by the Food and Drug Administration against certain medications and supplements.</p> <p>Case presentation</p> <p>A 69-year-old Latino man was referred to Hepatology Clinic for urgent evaluation of new onset jaundice, nausea and fatigue associated with a >40-fold increase in his transaminase levels and elevated INR and alkaline phosphatase. The patient had received a new prescription for varenicline to aid with smoking cessation approximately 3 weeks prior to his evaluation in Hepatology Clinic. Within 5 days of starting the varenicline, the patient developed new onset of nausea, vomiting, malaise and deep jaundice. The varenicline was discontinued on day 5 by the patient. Hepatologic evaluation revealed no evidence of acute viral hepatitis, autoimmune, metabolic or alcohol-related liver disorders. The patient’s past medical history was notable, however, for chronic hepatitis C. His liver enzymes and synthetic function completely normalized 9 weeks after discontinuation of the varenicline.</p> <p>Conclusion</p> <p>This report represents the second documented cases of drug-induced liver injury related to varenicline therapy, highlighting the need for clinician awareness regarding potential hepatotoxicity of varenicline, particularly among patients with pre-existing liver disease.</p> http://www.biomedcentral.com/1471-230X/12/65Drug induced liver injuryVareniclineIdiosyncratic |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sprague David Bambha Kiran |
spellingShingle |
Sprague David Bambha Kiran Drug-induced liver injury due to varenicline: a case report BMC Gastroenterology Drug induced liver injury Varenicline Idiosyncratic |
author_facet |
Sprague David Bambha Kiran |
author_sort |
Sprague David |
title |
Drug-induced liver injury due to varenicline: a case report |
title_short |
Drug-induced liver injury due to varenicline: a case report |
title_full |
Drug-induced liver injury due to varenicline: a case report |
title_fullStr |
Drug-induced liver injury due to varenicline: a case report |
title_full_unstemmed |
Drug-induced liver injury due to varenicline: a case report |
title_sort |
drug-induced liver injury due to varenicline: a case report |
publisher |
BMC |
series |
BMC Gastroenterology |
issn |
1471-230X |
publishDate |
2012-06-01 |
description |
<p>Abstract</p> <p>Background</p> <p>Liver injury due to prescription and nonprescription medications is an expanding public health concern in the United States, with drug-induced liver injury (DILI) being the single most common reason for regulatory actions instituted by the Food and Drug Administration against certain medications and supplements.</p> <p>Case presentation</p> <p>A 69-year-old Latino man was referred to Hepatology Clinic for urgent evaluation of new onset jaundice, nausea and fatigue associated with a >40-fold increase in his transaminase levels and elevated INR and alkaline phosphatase. The patient had received a new prescription for varenicline to aid with smoking cessation approximately 3 weeks prior to his evaluation in Hepatology Clinic. Within 5 days of starting the varenicline, the patient developed new onset of nausea, vomiting, malaise and deep jaundice. The varenicline was discontinued on day 5 by the patient. Hepatologic evaluation revealed no evidence of acute viral hepatitis, autoimmune, metabolic or alcohol-related liver disorders. The patient’s past medical history was notable, however, for chronic hepatitis C. His liver enzymes and synthetic function completely normalized 9 weeks after discontinuation of the varenicline.</p> <p>Conclusion</p> <p>This report represents the second documented cases of drug-induced liver injury related to varenicline therapy, highlighting the need for clinician awareness regarding potential hepatotoxicity of varenicline, particularly among patients with pre-existing liver disease.</p> |
topic |
Drug induced liver injury Varenicline Idiosyncratic |
url |
http://www.biomedcentral.com/1471-230X/12/65 |
work_keys_str_mv |
AT spraguedavid druginducedliverinjuryduetovareniclineacasereport AT bambhakiran druginducedliverinjuryduetovareniclineacasereport |
_version_ |
1724965138227789824 |